U.S. Tech Hardware Stock News

Archer Aviation (NYSE:ACHR) has partnered with Starlink to equip its Midnight electric air taxis with high speed satellite internet. The agreement introduces low Earth orbit satellite connectivity to Archer’s fleet, targeting both passenger wifi and operational communications. This marks Starlink’s first move into the emerging urban air mobility sector, with Archer as its initial partner. Archer Aviation’s shares most recently closed at $7.115, with the stock showing a 2.7% gain over the...

Why F&G Annuities & Life is Drawing Attention Now F&G Annuities & Life (FG) has been catching investor attention after a period of weak share performance, including a return of about negative 45% over the past year and negative 25% year to date. At the same time, the company reports revenue of US$5,731.0 million and net income of US$248.0 million. This provides a concrete earnings base to weigh against the recent share price pressure. See our latest analysis for F&G Annuities & Life. With the...

If you are wondering whether Brady is fairly priced or starting to look stretched, its current setup gives you quite a bit to think about before making any moves. The stock last closed at US$92.46, with returns of 3.5% over 7 days, 8.6% over 30 days, 17.6% year to date, 29.3% over 1 year, 72.4% over 3 years and 83.9% over 5 years, which naturally raises questions about how much of the story is already in the share price. Recent coverage has focused on Brady as a steady industrial...

Amphastar Pharmaceuticals (AMPH) closed out FY 2025 with Q4 revenue of US$183.1 million and basic EPS of US$0.53, alongside net income of US$24.4 million. The trailing twelve months showed revenue of US$719.9 million and EPS of US$2.10. Over the past six quarters, revenue has ranged between US$170.5 million and US$191.8 million per quarter, with basic EPS moving between US$0.37 and US$0.83. This leaves investors focused squarely on how efficiently that top line is converting into profit...

Onto Innovation (NYSE:ONTO) reported record quarterly net sales, while profitability metrics remained under pressure. Management highlighted ongoing supply chain and geopolitical risks affecting operations and cost structure. The company pointed to its patent portfolio and recent acquisitions as key supports for its business model. For investors watching the semiconductor equipment space, Onto Innovation has a current share price of $215.89 and a 30.2% gain year to date. Over the past year,...

Alphabet's Google received conditional approval from South Korean authorities to export high precision map data, following years of regulatory resistance. The decision comes with strict security requirements, including measures to protect sensitive locations and data handling. This approval is expected to allow more advanced mapping and navigation features for users in South Korea. Alphabet, traded as NasdaqGS:GOOGL, last closed at $311.687. The stock is up 83.8% over the past year and has...

Recent performance context for CBIZ stock CBIZ (CBZ) has drawn attention after a period of weak share performance, with the stock showing negative returns over the past month, past 3 months, year to date, and over the past year. See our latest analysis for CBIZ. With the share price now at $28.64, CBIZ’s 1 day share price return of 9.94% decline caps a weak spell that includes a 30 day share price return of 25.71% decline and a 1 year total shareholder return of 63.36% loss. This points to...

Wondering if Snowflake is starting to look interesting at today’s price, or if it still feels expensive for what you get? This article focuses on what you are actually paying for and how that lines up with different ways of valuing the business. After closing at US$168.41, Snowflake’s share price reflects a 2.4% decline over the last 7 days, a 22.0% decline over the last month, and a 22.3% decline year to date, with a 4.9% decline over the past year and a 29.8% decline over 5 years, while...

In February 2026, Five9 reported full-year 2025 results showing revenue of US$1,149.09 million and net income of US$39.42 million, and issued 2026 guidance calling for revenue between US$1.247 billion and US$1.261 billion with positive GAAP earnings per share. The company also highlighted rapidly expanding enterprise AI activity, with AI-related bookings and revenue becoming a more meaningful contributor alongside its core subscription business and Google Cloud partnership. We’ll now look at...

If you are wondering whether Digi International's current share price lines up with its underlying worth, this piece will walk through the key valuation checks that matter most. The stock last closed at US$48.82, with recent returns of 8.7% over 30 days, 13.1% year to date and 59.9% over 1 year, alongside a 2.7% decline over the past week and a 174.7% return over 5 years. Recent news coverage has focused on Digi International's position as a provider of connectivity and IoT solutions and how...

If you are wondering whether Americold Realty Trust is priced attractively right now, this article will walk you through what the numbers are really saying about its value. The stock recently closed at US$13.43, with returns of 0.1% over the last 7 days, 9.2% over 30 days, 3.7% year to date, and longer term moves of a 37.8% decline over 1 year, a 49.1% decline over 3 years, and a 53.0% decline over 5 years. Recent coverage around Americold has focused on its position within the real estate...

Booking Holdings (NasdaqGS:BKNG) has announced a 25-for-1 stock split, aiming to make its high-priced shares more accessible to a wider base of investors. The company also revealed a new media solution through its OpenTable platform, creating paid partnership and advertising opportunities for restaurant and brand partners. Booking Holdings comes into these announcements with a share price of $4,239.35 and a mixed return profile, including a 4.0% gain over the past week alongside a 16.6%...

Honeywell International (NasdaqGS:HON) is progressing through a wide portfolio reshaping that includes planned asset sales and an anticipated spin off of its aerospace and automation businesses. The company has amended its acquisition agreement for Johnson Matthey's Catalyst Technologies business, revising the purchase price and timing of the deal. Institutional investors have recently initiated new positions in Honeywell, citing that the impact of these portfolio moves is not fully...

KBR (KBR) is back in focus after a busy earnings week, combining a major Majnoon oil field contract in Iraq with fourth quarter results that paired lower revenue with higher net income and confirmed 2026 guidance. See our latest analysis for KBR. The latest contract wins and confirmed 2026 guidance arrive after a period where the share price has been relatively muted. The 90 day share price return is 2.45% and the 1 year total shareholder return shows a decline of 12.70%, while the 5 year...

Pool Corp (POOL) has wrapped up FY 2025 with fourth quarter revenue of US$982.2 million and basic EPS of US$0.86, alongside trailing twelve month revenue of about US$5.3 billion and EPS of US$10.89. This gives investors a clear snapshot of both its seasonal quarter and full year earnings power. The company has seen quarterly revenue range from US$982.2 million in Q4 2025 to US$1.8 billion in Q2 2025, while basic EPS moved between US$0.86 and US$5.19 over the same period. This sets the...

If you are wondering whether AECOM at around US$97.54 is offering fair value or a potential mismatch between price and fundamentals, you are in the right place. The stock has been relatively steady in the short term, with a 0.4% decline over the last 7 days and a 0.1% move over 30 days, while the longer view shows a 1.2% return year to date, an 11.9% return over 3 years and a 74.1% return over 5 years. Recent coverage of AECOM has focused on its position as a large player in capital projects...

Xeris Biopharma Holdings (XERS) has drawn attention after recent share price pressure, with the stock down over the month and past 3 months, despite positive annual revenue and net income growth figures. See our latest analysis for Xeris Biopharma Holdings. At a latest share price of US$6.12, Xeris Biopharma’s weaker recent share price returns over the past month and quarter contrast with a much stronger 1 year and 3 year total shareholder return. This suggests that momentum has cooled after...

In recent weeks, Micron Technology has highlighted unprecedented demand for its high-bandwidth memory and DRAM, with its entire 2026 HBM output already contracted and multi-year capacity expansions underway in the US, Japan, and New York to address an industry-wide memory shortage tied to AI data centers. This combination of fully booked premium memory supply, long-term contracts, and large-scale capacity investment is giving Micron unusually high revenue visibility in a usually cyclical...

Photronics reported record high end integrated circuit revenue for the second consecutive quarter. The company is expanding facilities to broaden its geographic revenue mix as chipmaking becomes more regionally focused. Insiders have been consistently selling shares without any reported insider purchases over the same period. Photronics, trading on NasdaqGS:PLAB, is drawing attention after back to back record quarters for high end integrated circuit revenue alongside an active facility...

Why Encore Capital Group is on investors’ radar Encore Capital Group (ECPG) has been drawing attention after a strong recent share price move, with returns over the past month and past 3 months standing out against its longer term track record. See our latest analysis for Encore Capital Group. The recent momentum has been strong, with a 6.8% 1 day share price return adding to a 26.7% 30 day share price return and an 81.1% 1 year total shareholder return, which points to shifting expectations...

If you are wondering whether CME Group at around US$319.50 is still offering value after its recent run, this article walks through what the current price might be implying about the business. The stock has posted returns of 3.7% over the past week, 11.7% over the last 30 days, 18.5% year to date and 28.3% over the past year, with a 3 year return of 92.8% and 5 year return of 80.5%. Recent coverage has focused on CME Group's role as a major exchange operator and its position in global...

Nuvation Bio recently finalized a protocol amendment that expands its global SIGMA study of safusidenib into a Phase 3 trial, broadening eligibility to include patients with high‑risk grades 2 and 3 and grade 4 IDH1‑mutant astrocytoma after standard‑of‑care treatment. This shift into a registrational Phase 3 setting materially advances safusidenib within Nuvation Bio’s pipeline, potentially reshaping the company’s role in treating aggressive IDH1‑mutant brain tumors. Next, we’ll examine how...

If you are wondering whether Wyndham Hotels & Resorts is pricing in too much optimism or still offering value, this article will walk you through what the current share price could be telling you. The stock last closed at US$81.80, after a 12.4% gain over the past month, while it shows a 23.0% decline over the past year and a 37.0% return over five years. Recent news flow around Wyndham has centered on its position in the global hotel and franchising space, including attention on how brand...

Pfizer received full FDA approval for BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil based chemotherapy for BRAF V600E mutant metastatic colorectal cancer. The decision is based on Phase 3 BREAKWATER trial results and establishes the regimen as a new first line standard of care in this setting. The approval expands treatment options for oncologists and deepens Pfizer's presence in colorectal cancer within its oncology portfolio. For investors watching NYSE:PFE, this...